In the context of periodontitis, the administration of low‐dose IL‐2 has been proposed as a potential therapeutic strategy to boost Treg populations and restore immune homeostasis, thereby controlling excessive inflammation and bone resorption (Whiteside 2015). The gene discussed is IL2; the disease is periodontitis.